A study of 3,159 people monitored over multiple nights found that high night-to-night variability in sleep apnea severity independently increased the odds of major cardiovascular events by 34% — suggesting that standard one-night sleep tests may underestimate risk for a hidden group of patients.
A Mount Sinai study published in Nature Communications Medicine introduces a machine learning model that can predict whether CPAP therapy will reduce or increase cardiovascular risk for individual sleep apnea patients — a first step toward personalized treatment decisions.
A review in Respirology finds that four distinct biological mechanisms drive obstructive sleep apnea in different patients, and that matching treatments to each mechanism could transform care — especially for the millions who abandon CPAP.
A Yale study of nearly 1 million U.S. veterans found that people with both insomnia and obstructive sleep apnea face nearly four times the risk of cardiovascular disease compared to those without either condition.
A large European clinical trial found that sulthiame, an existing epilepsy medication, reduced breathing interruptions during sleep by up to 47% in patients with moderate to severe obstructive sleep apnea, raising hopes for a pharmaceutical alternative to CPAP therapy.
Pharmaceutical company Apnimed plans to file for FDA approval of AD109 in early 2026 after the drug met its primary endpoint in a second Phase 3 trial, potentially offering relief to patients who struggle with CPAP therapy.
UC Davis Medical Center became the first hospital in Northern California to implant the Genio system, an FDA-approved device that stimulates nerves to keep airways open during sleep without requiring an internal battery.